TrialThe clinical respiratory journal2025

The Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) as Predictive Tool in Hospitalised Patients With Community-Acquired Pneumonia (CAP).

Lisa Hessels et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.